Older Adults' Attitudes Towards Stopping Aspirin

NCT07305376 | Completed

• 1 other identifier: HUM00280646
• Study Type: interventional
• Target: 2,819
• Locations: 1 country
• Sites: 1

Brief Summary

This online, survey-based experiment will include 2,400 adults who are 65 years and older (n=1,200 each from the United States and Australia). Each participant will be asked to share their opinions on a hypothetical patient scenario developed by our multidisciplinary team. This work is expected to significantly contribute to the understanding of how older adults make decisions about deprescribing medications. The long-term goal is to enhance communication between older adults and clinicians so that medication regimens are optimized and align with care preferences. These results will directly inform future research on the impact of communication choices in clinical practice.

Conditions

Medication Overuse

Outcome Measures

Primary Outcomes (2)

• "How safe do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale

  Day 1

• "How helpful do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale

  Day 1

Study Arms (3)

Source of recommendation - Physician

EXPERIMENTAL

Participants read a hypothetical scenario where a doctor recommends stopping aspirin.

Other: Additional harm information; Other: Less information

Source of recommendation - Pharmacist

EXPERIMENTAL

Participants read a hypothetical scenario where a pharmacist recommends stopping aspirin.

Other: Additional harm information; Other: Less information

Source of information - AI

EXPERIMENTAL

Participants read a hypothetical scenario where artificial intelligence is used to recommend stopping aspirin.

Other: Additional harm information; Other: Less information

Interventions

Less information OTHER

Participants will receive less information about the risk of harms of continuing aspirin.

Source of information - AI; Source of recommendation - Pharmacist; Source of recommendation - Physician

Additional harm information OTHER

Participants received additional information about the harm of continuing aspirin.

Source of information - AI; Source of recommendation - Pharmacist; Source of recommendation - Physician

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)

You may qualify if:

• Reside in Australia or the United States
• years and older

You may not qualify if:

• Unable to read survey written in English

Sponsors & Collaborators

• University of Michigan: lead
• University of Sydney: collaborator

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Prescription Drug Overuse

Condition Hierarchy (Ancestors)

Prescription Drug Misuse; Drug Misuse; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Sarah Vordenberg, PharmD, MPH

  University of Michigan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Chair and Clinical Professor Department of Clinical Pharmacy

Study Record Dates

• First Submitted: November 13, 2025
• First Posted: December 26, 2025
• Study Start: November 10, 2025
• Primary Completion: November 30, 2025
• Study Completion: November 30, 2025
• Last Updated: April 29, 2026

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)